person · Reporting owner

ROOT JONATHAN D

Disclosed activity across 10 companies

Tapewire entity: 29762
SEC CIK: 0001225480

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SBTX · Entity 883	Director	June 10, 2022	June 13, 2022
CARLSMED, INC.CARL · Entity 5551	Director	June 03, 2026	June 22, 2026
Edgewise Therapeutics, Inc.EWTX · Entity 3965	Director	June 05, 2026	July 17, 2026
Omada Health, Inc.OMDA · Entity 2364	Director	October 05, 2026	October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 10, 2022 · Filed June 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09	Direct	18,000	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

CARLSMED, INC.

Report date June 03, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	497,697	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Grant · Acquired 13,698 · Balance 497,697 F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	4,305,806	Reported balance Holding disclosure · report date 2026-06-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,305,806 F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	218,524	Reported balance Holding disclosure · report date 2026-06-03 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 218,524 F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	1,117,743	Reported balance Holding disclosure · report date 2026-06-03 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,117,743 F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII").

F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A").

F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A").

F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.

Edgewise Therapeutics, Inc.

Report date June 05, 2026 · Filed July 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05	Direct	16,377	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.

Omada Health, Inc.

Report date October 05, 2026 · Filed October 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	192,571	Reported balance After 2026-10-05 transaction · row 1 1 source row Row 1 · 2026-10-05 · Grant · Acquired 694 · Balance 192,571 F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BOX INC

Report date June 02, 2017 · Filed June 08, 2017 · Amendment

Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M

Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP IX	0	Last balance in matching sequence After 2017-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Class B Common StockSEC Table II · derivative / convertible security	IndirectDirectly owned by USVP IX	3,713,775	Reported balance After 2017-06-02 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

INTERMOLECULAR INC

Report date November 08, 2018 · Filed November 13, 2018

Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M

Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by USVP IX	0	Reported balance After 2018-11-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	Direct	856,155	Reported balance After 2018-11-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common Stock, $0.001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2018-11-08 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Steven Krausz	97,593	Last balance in matching sequence After 2018-11-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by David Liddle	69,609	Reported balance After 2018-11-08 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Paul Matteucci	60,408	Reported balance After 2018-11-08 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Jonathan Root	85,851	Reported balance After 2018-11-08 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Casey Tansey	60,336	Reported balance After 2018-11-08 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Philip Young	82,370	Reported balance After 2018-11-08 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Inari Medical, Inc.

Report date February 19, 2025 · Filed February 20, 2025

Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-19 transaction · row 1 1 source row Row 1 · 2025-02-19 · Other · Disposed 541,149 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectDirectly Owned by Spouse	0	Reported balance After 2025-02-19 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-02-19 · Other · Disposed 335 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

Inspire Medical Systems, Inc.

Report date November 08, 2018 · Filed November 14, 2018

Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, YOUNG PHILIP M

Section 16 reporting ended · disclosed 2018-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP IX	1,084,127	Reported balance After 2018-11-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-11-08 · Other · Disposed 1,084,127 · Balance 1,084,127 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	216,825	Reported balance After 2018-11-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-11-08 · Other · Acquired 216,825 · Balance 216,825 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-11-08 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-11-08 · Other · Disposed 216,825 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Irwin Federman	18,212	Reported balance After 2018-11-08 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Steven Krausz	22,573	Reported balance After 2018-11-08 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2018-11-08 · Other · Acquired 22,573 · Balance 22,573 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by David Liddle	15,391	Reported balance After 2018-11-08 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2018-11-08 · Other · Acquired 15,391 · Balance 15,391 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Paul Matteucci	13,356	Reported balance After 2018-11-08 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2018-11-08 · Other · Acquired 13,356 · Balance 13,356 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Jonathan Root	18,982	Reported balance After 2018-11-08 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2018-11-08 · Other · Acquired 18,982 · Balance 18,982 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Philip Young	18,212	Reported balance After 2018-11-08 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

OncoMed Pharmaceuticals Inc

Report date April 23, 2019 · Filed April 23, 2019

Section 16 reporting ended · disclosed 2019-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-04-23 transaction · row 1 1 source row Row 1 · 2019-04-23 · Other · Disposed 121,020 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.

Filing footnotes · ownership attribution and instrument terms

F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.

F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.

eFFECTOR Therapeutics, Inc.

Report date August 01, 2022 · Filed August 03, 2022

Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, Tansey Casey M

Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP X	3,981,940	Last balance in matching sequence After 2022-08-03 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by AFF X	127,569	Last balance in matching sequence After 2022-08-03 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 08, 2018 Filed Nov 14, 2018 01:13 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	OtherCommon Stock	22,573	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 5 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Steven Krausz Disclosed balance after: 22,573 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	OtherCommon Stock	18,212	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 4 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Irwin Federman Disclosed balance after: 18,212 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	OtherCommon Stock	216,825	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 3 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	OtherCommon Stock	216,825	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 2 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,825 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. Read SEC document
November 08, 2018 Filed Nov 14, 2018 01:13 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	OtherCommon Stock	1,084,127	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 1 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 1,084,127 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	82,370	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 11 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Philip Young Disclosed balance after: 82,370 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	60,336	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 10 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Casey Tansey Disclosed balance after: 60,336 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	85,851	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 9 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Jonathan Root Disclosed balance after: 85,851 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	60,408	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 8 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Paul Matteucci Disclosed balance after: 60,408 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	69,609	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 7 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by David Liddle Disclosed balance after: 69,609 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	102,093	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 4 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Steven Krausz Disclosed balance after: 102,093 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	856,155	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 3 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	856,155	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 2 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,155 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. Read SEC document
November 08, 2018 Filed Nov 13, 2018 22:18 UTC	INTERMOLECULAR INC IMI · Entity 154785	OtherCommon Stock, $0.001 per share	4,280,779	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 1 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 22, 2018 Filed Jun 25, 2018 18:07 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001140361-18-029838 · doc1.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries F Convertible Preferred Stock · Derivative	3,795,620	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 12 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 570,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries E Convertible Preferred Stock · Derivative	948,855	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 11 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 163,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F3 · derivative.exercise_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F3 · derivative.expiration_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries D Convertible Preferred Stock · Derivative	1,397,478	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 10 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 210,147 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries C Convertible Preferred Stock · Derivative	3,142,670	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 9 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 472,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries B Convertible Preferred Stock · Derivative	2,102,315	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 8 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 389,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionSeries A Convertible Preferred Stock · Derivative	2,400,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-031866 · a4.xml · derivative · entry 7 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 360,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	570,769	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 6 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,168,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	163,962	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 5 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,597,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	210,147	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 4 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,433,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	472,581	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 3 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,223,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	389,893	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 2 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 750,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
May 07, 2018 Filed May 10, 2018 01:19 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	ConversionCommon Stock	360,902	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-031866 · a4.xml · nonDerivative · entry 1 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 360,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 5, 2017 18:35 UTC	BOX INC BOX · Entity 3932	ConversionClass B Common Stock · Derivative	8,000,000	$0.00	$0.00	Disclosure SEC source: 0001548538-17-000012 · edgar.xml · derivative · entry 3 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 3,713,775 Underlying: Class A Common Stock · 8,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.underlying_shares: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 5, 2017 18:35 UTC	BOX INC BOX · Entity 3932	OtherClass A Common Stock	8,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-17-000012 · edgar.xml · nonDerivative · entry 2 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 0 F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: Prorata distribution in kind from the partnership without consideration to its limited partners. F2 · price: Prorata distribution in kind from the partnership without consideration to its limited partners. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 5, 2017 18:35 UTC	BOX INC BOX · Entity 3932	ConversionClass A Common Stock	8,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-17-000012 · edgar.xml · nonDerivative · entry 1 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 8,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 8, 2017 23:42 UTC Amendment	BOX INC BOX · Entity 3932	ConversionClass B Common Stock · Derivative	8,000,000	$0.00	$0.00	Disclosure SEC source: 0001548538-17-000015 · edgar.xml · derivative · entry 3 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 3,713,775 Underlying: Class A Common Stock · 8,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.underlying_shares: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 8, 2017 23:42 UTC Amendment	BOX INC BOX · Entity 3932	OtherClass A Common Stock	8,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-17-000015 · edgar.xml · nonDerivative · entry 2 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 0 F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: Prorata distribution in kind from the partnership without consideration to its limited partners. F2 · price: Prorata distribution in kind from the partnership without consideration to its limited partners. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 02, 2017 Filed Jun 8, 2017 23:42 UTC Amendment	BOX INC BOX · Entity 3932	ConversionClass A Common Stock	8,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001548538-17-000015 · edgar.xml · nonDerivative · entry 1 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP IX Disclosed balance after: 8,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document
June 01, 2017 Filed Jun 2, 2017 16:59 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $3.30	$0.00	Disclosure SEC source: 0001140361-17-023619 · doc1.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
May 26, 2017 Filed May 26, 2017 11:57 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	3,222	$3.70	$11,927.20	Disclosure SEC source: 0001548538-17-000009 · edgar.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-B Disclosed balance after: 0 F1 · price: Represents a weigthed average sales price of all trades for the day for the direct owner. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 26, 2017 Filed May 26, 2017 11:57 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	6,358	$3.70	$23,536.04	Disclosure SEC source: 0001548538-17-000009 · edgar.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-A Disclosed balance after: 0 F1 · price: Represents a weigthed average sales price of all trades for the day for the direct owner. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 24, 2017 Filed May 26, 2017 11:57 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	1,447	$3.72	$5,376.76	Disclosure SEC source: 0001548538-17-000009 · edgar.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-B Disclosed balance after: 3,222 F1 · price: Represents a weigthed average sales price of all trades for the day for the direct owner. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 24, 2017 Filed May 26, 2017 11:57 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	2,853	$3.72	$10,601.18	Disclosure SEC source: 0001548538-17-000009 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-A Disclosed balance after: 6,358 F1 · price: Represents a weigthed average sales price of all trades for the day for the direct owner. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 19, 2017 Filed May 22, 2017 20:16 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	2,519	$3.70	$9,323.57	Disclosure SEC source: 0001548538-17-000007 · edgar.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-B Disclosed balance after: 4,669 F1 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 19, 2017 Filed May 22, 2017 20:16 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	4,968	$3.70	$18,388.06	Disclosure SEC source: 0001548538-17-000007 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-A Disclosed balance after: 9,211 F1 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 16, 2017 Filed May 18, 2017 16:49 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	2,321	$3.58	$8,313.36	Disclosure SEC source: 0001548538-17-000005 · edgar.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-B Disclosed balance after: 7,188 F1 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 16, 2017 Filed May 18, 2017 16:49 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	SaleCommon Stock	4,579	$3.58	$16,401.06	Disclosure SEC source: 0001548538-17-000005 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by EP VIII-A Disclosed balance after: 14,179 F1 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 11, 2017 Filed May 15, 2017 18:42 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	OtherCommon Stock	19,215	$0.00	$0.00	Disclosure SEC source: 0001140361-17-020846 · doc1.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF VIII Disclosed balance after: 0 F1 · kind: Certain funds associated with the reporting person completed a distribution of shares to their limited partners (the "Distribution"). In connection with the Distribution, the reporting person received shares of common stock of the Issuer for no consideration. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 11, 2017 Filed May 15, 2017 18:42 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	OtherCommon Stock	1,990,783	$0.00	$0.00	Disclosure SEC source: 0001140361-17-020846 · doc1.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP VIII Disclosed balance after: 0 F1 · kind: Certain funds associated with the reporting person completed a distribution of shares to their limited partners (the "Distribution"). In connection with the Distribution, the reporting person received shares of common stock of the Issuer for no consideration. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein. Read SEC document
May 11, 2017 Filed May 15, 2017 18:42 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	OtherCommon Stock	55,929	$0.00	$0.00	Disclosure SEC source: 0001140361-17-020846 · doc1.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,020 F1 · kind: Certain funds associated with the reporting person completed a distribution of shares to their limited partners (the "Distribution"). In connection with the Distribution, the reporting person received shares of common stock of the Issuer for no consideration. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.